In dermatology, monoclonal antibodies targeting tumor necrosis factor alpha (TNF-α) and specific interleukins (ILs) are particularly effective in the treatment of psoriasis, given the central role of the IL-23/Th17 axis in the disease’s pathogenesis [3,4]. Here, TNF is linked to psoriasis.